Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 9/20 | 0.41 |
| ▸ | RORC | P51449 | 4/20 | 0.40 |
| ▸ | MLNR | O43193 | 2/20 | 0.40 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.37 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19377287 | 0.86 | RORC (0.45) | DRD2HTR2AHTR2CDRD3HTR6 | |
| SCHEMBL19377304 | 0.85 | NAMPT (0.60) | NAMPTRORCGHSR | |
| SCHEMBL19377221 | 0.85 | NPC1 (0.46) | DRD2HTR2AHTR2CDRD3HTR6 | |
| SCHEMBL19406974 | 0.83 | DRD2 (0.47) | DRD2HTR2AHTR2CDRD3HTR6 | |
| SCHEMBL19377329 | 0.82 | DRD2 (0.42) | DRD2HTR2AHTR2CDRD3HTR6 | |
| SCHEMBL24800255 | 0.81 | NAMPT (0.48) | EPHX2NAMPTRORC | |
| SCHEMBL19377046 | 0.79 | EPHX2 (0.46) | DRD2HTR2AHTR2CDRD3HTR6 | |
| SCHEMBL19377151 | 0.79 | NAMPT (0.50) | NAMPTRORC | |
| SCHEMBL30162472 | 0.79 | NAMPT (0.50) | NAMPTRORC | |
| SCHEMBL19377317 | 0.79 | HSD17B10 (0.48) | EPHX2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | claimed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | US | disclosed |
| WO-2017162390-A1 | BENZENESULFONYL-ASYMMETRIC UREAS AND MEDICAL USES THEREOF | HELSINN HEALTHCARE SA (CH) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275301-A1 | Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof | UTS2R, GHSR, GRPR | DRD2 4443/4885HTR2A 292/4885HTR2C 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.